An Unmet Need.

Slides:

Advertisements

Similar presentations

Addressing the Challenges in Primary and Secondary Stroke Prevention

Advertisements

Sites of Action in Coagulation System Novel Factor Xa and DT Inhibitors.

Burden of Atrial Fibrillation The Percentage of Strokes Attributable to AF Increases With Age.

NOACs for Cancer-Associated Thrombosis:

Managing Bleeds in Patients Anticoagulated With Warfarin and Other Agents.

Clinical Considerations in the Management of EGFR-Mutated Advanced NSCLC.

NOACs In Long-term VTE Treatment: A State Of The Art Review

US Guidelines US Guidelines Low-risk Patients.

When Is Adding Aspirin to NOACs Worth the Risk?

Barriers to Oral Anticoagulant Use for Stroke Prevention in AF

The Burden of Hospital-Associated Venous Thromboembolism

Thrombosis, Cancer, and NOACs

Access to NOAC Therapy:

NOACs in Clinical Practice: Are They All the Same?

Introduction ESC Annual Meeting in Review: NOACs and NVAF: Real-World Data, Guidelines, and More.

New Strategies to Prevent CV Events After Hospital Discharge

Emergency Management of NOAC Bleeding

The Safety and Efficacy of Full vs

Anticoagulation Highlights From the American Heart Association Meeting 2017.

Up to Date on Which NOAC for Which Patient

Clinical Presentations of VTEa,b NOACs VTE Acute Treatment Trials.

Through Thick and Thin.

Global Burden of VTE. Preventing Thrombosis During and Post-Hospitalization: New Paradigms in Clinical Care.

Surveying the Safety of NOACs in the Real World

Selecting NOACs for High-Risk Patients

Panelists. One Size May Not Fit All: A New Aspirin Option for the High-Risk Patient.

A Case Challenge: Anticoagulant Choices for Acute PE

NOAC Use in AF: REAL-WORLD Studies WITH REAL RESULTS

The Essentials for Secondary Stroke Prevention

Assessing the Risk for Stroke in Patients With Atrial Fibrillation

New Oral Anticoagulants and VTE Management

VTE Treatment Conventional Approach

Efficacy and Safety of Edoxaban in Patients With AF and HF

Access to NOAC Therapy:

Antithrombotic Protection in CAD and HF

PCSK9 Inhibitors and Cardiovascular Outcomes

Learning Objectives Classification of VTE Goals of VTE Treatment.

A Better Solution For Cancer Patients With VTE?

Reversal Strategies for VKA: Truths and Misconceptions

Oral Anticoagulation in AF

Forest plot of the HRs for DOACs vs warfarin for (A) new or recurrent VTE and (B) major bleeding based on the published subanalyses of the patients with.

Real-World Evidence in VTE

Dos and Don’ts for High-Risk Elderly Patients With AF

Extending Treatment for Thrombosis: What’s the Right Choice?

Practical Considerations to Extend Treatment for VTE

Extraordinary Cases of VTE Prevention in Patients With Cancer

Treatment of Thromboembolic Disease The Need for Multiple Perspectives

Anticoagulation and Thrombosis Management

Trials and Tribulations in VTE: How Do Real-World Data Fit In?

Factor Xa Inhibitors in PAD

CAD/PAD in Primary Care

A Time for Change for Managing Patients With VTE Who Have Cancer

Cancer-Associated Thrombosis

Improving Outcomes in AF: Do the NOACs Hold Their Promise In The Real World?

Managing Pulmonary Embolism Posthospital Discharge

NOAC Studies in VTE AF Studies Superior Outcomes.

Extraordinary Cases in VTE

Program Goals Background: Anticoagulation in Patients With VTE.

Treatment and secondary prevention strategy diagram for VTE in patients with active cancer based on the treatment guidelines for cancer-associated VTE.

Disease Burden of VTE Phases of VTE Treatment.

5 Good Minutes on Atrial Fibrillation-related Stroke

At the Crossroads of Coagulation

VTE Treatment and Secondary Prevention VTE Treatment Trials Initial Dosing.

Treatment Advances for RA

PCSK9 Inhibitors and Real-World Evidence

Extraordinary Cases in Stroke Prevention

Antithrombotic Therapy in AF Patients Undergoing PCI

Can the Dual vs Triple Therapy Controversy in Patients With AF Undergoing PCI Be Put to Rest?

Translating Data From Trial to Practice

Presentation transcript:

An Unmet Need

Program Goals

Disease Burden of VTE

Cancer and VTE

Risk Factors for Developing VTE in Patients with Cancer

Guideline Recommendations Treatment and Secondary Prophylaxis of Cancer-Associated VTE

Treatment Issues With Anticoagulation

Subgroup Analysis of Patients With Active Cancer Efficacy and Safety of NOACs vs VKA

Efficacy and Safety of NOACs in Cancer vs No Cancer

Hokusai-VTE Study

Hokusai-VTE: Subgroup Analysis of Edoxaban for VTE in Patients With Cancer

Treatment and Secondary Prevention Strategy for VTE in Patients With Active Cancer

Hokusai-VTE Cancer Study

Prevention of VTE in Patients With Cancer Primary Thromboprophylaxis

NOACs for Thromboprophylaxis in Medically Ill Patients

Heterogeneity of Populations in Cancer Subgroups of NOAC Trials

VTE Primary Prophylaxis in Cancer

Take-Home Messages

Abbreviations